NATCO Pharma Dividends and Buybacks
Dividend criteria checks 4/6
NATCO Pharma is a dividend paying company with a current yield of 0.49% that is well covered by earnings.
Key information
0.5%
Dividend yield
0%
Buyback Yield
| Total Shareholder Yield | 0.5% |
| Future Dividend Yield | 0.5% |
| Dividend Growth | 4.5% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | ₹5.750 |
| Payout ratio | 5% |
Recent dividend and buyback updates
NATCO Pharma (NSE:NATCOPHARM) Has Announced A Dividend Of ₹1.50
Nov 18
NATCO Pharma (NSE:NATCOPHARM) Is Due To Pay A Dividend Of ₹1.25
Feb 21Recent updates
Investors Aren't Buying NATCO Pharma Limited's (NSE:NATCOPHARM) Earnings
Dec 23Is NATCO Pharma (NSE:NATCOPHARM) Using Too Much Debt?
Dec 08NATCO Pharma (NSE:NATCOPHARM) Has Announced A Dividend Of ₹1.50
Nov 18Earnings Beat: NATCO Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Nov 15We Ran A Stock Scan For Earnings Growth And NATCO Pharma (NSE:NATCOPHARM) Passed With Ease
Oct 13NATCO Pharma Limited's (NSE:NATCOPHARM) Shares Bounce 26% But Its Business Still Trails The Market
Aug 13If EPS Growth Is Important To You, NATCO Pharma (NSE:NATCOPHARM) Presents An Opportunity
Jul 15NATCO Pharma (NSE:NATCOPHARM) Seems To Use Debt Rather Sparingly
Jun 30NATCO Pharma Limited's (NSE:NATCOPHARM) Earnings Are Not Doing Enough For Some Investors
Jun 14NATCO Pharma Limited (NSE:NATCOPHARM) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models
May 30Calculating The Fair Value Of NATCO Pharma Limited (NSE:NATCOPHARM)
May 09Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?
Apr 03NATCO Pharma (NSE:NATCOPHARM) Is Due To Pay A Dividend Of ₹1.25
Feb 21NATCO Pharma Limited Just Beat EPS By 223%: Here's What Analysts Think Will Happen Next
Feb 18NATCO Pharma Limited (NSE:NATCOPHARM) Surges 25% Yet Its Low P/E Is No Reason For Excitement
Feb 17Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jan 25An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 37% Undervalued
Jan 09Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?
Dec 13An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 42% Undervalued
Sep 30Here's Why We Think NATCO Pharma (NSE:NATCOPHARM) Might Deserve Your Attention Today
Sep 12NATCO Pharma (NSE:NATCOPHARM) Is Paying Out A Larger Dividend Than Last Year
Aug 12Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jul 16NATCO Pharma Limited (NSE:NATCOPHARM) Shares Could Be 44% Below Their Intrinsic Value Estimate
Apr 20Is NATCO Pharma Limited (NSE:NATCOPHARM) Trading At A 46% Discount?
Dec 20NATCO Pharma's (NSE:NATCOPHARM) Upcoming Dividend Will Be Larger Than Last Year's
Aug 12Stability and Growth of Payments
Fetching dividends data
Stable Dividend: NATCOPHARM's dividend payments have been volatile in the past 10 years.
Growing Dividend: NATCOPHARM's dividend payments have increased over the past 10 years.
Dividend Yield vs Market
| NATCO Pharma Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (NATCOPHARM) | 0.5% |
| Market Bottom 25% (IN) | 0.3% |
| Market Top 25% (IN) | 1.2% |
| Industry Average (Pharmaceuticals) | 0.7% |
| Analyst forecast (NATCOPHARM) (up to 3 years) | 0.5% |
Notable Dividend: NATCOPHARM's dividend (0.49%) is higher than the bottom 25% of dividend payers in the Indian market (0.26%).
High Dividend: NATCOPHARM's dividend (0.49%) is low compared to the top 25% of dividend payers in the Indian market (1.22%).
Earnings Payout to Shareholders
Earnings Coverage: With its low payout ratio (5.3%), NATCOPHARM's dividend payments are thoroughly covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its low cash payout ratio (8%), NATCOPHARM's dividend payments are thoroughly covered by cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/01 20:45 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
NATCO Pharma Limited is covered by 27 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nitin Bhasin | Ambit Capital |
| Prashant Nair | Ambit Capital |
| Sriraam Rathi | Anand Rathi Shares and Stock Brokers Limited |